












⑥ Nivolumab With or Without Ipilimumab in Patients With Recurrent or Metastatic Merkel Cell Carcinoma: A Nonrandomized, Open-Label, International, Multicenter Phase I/II Study

Shailender Bhatia, MD¹ ; Suzanne L. Topalian, MD² ; William Sharfman, MD² ; Tim Meyer, MBBS, PhD³ ; Neil Steven, MBBS, PhD⁴ ; Christopher D. Lao, MD⁵; Lorena Fariñas-Madrid, MD⁶; Lot A. Devriese, MD, PhD⁷; Kathleen Moore, MD⁸ ; Robert L. Ferris, MD, PhD⁹ ; Yoshitaka Honma, MD¹⁰ ; Ileana Elias, MD¹¹; Anjaiah Srirangam, PhD¹¹; Charlie Garnett-Benson, PhD¹¹ ; Michelle Lee, PhD^{11,12}; and Paul Nghiem, MD, PhD¹³ 